 |
 |
|
|
|
|
|
 |
 |
 |
 |
|
 |
 |
 |
|||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
|
|
||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||
 |
 |
||||||
 |
|
||||||
 |
|
||||||
|
|
||||||
 |
 |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
July
12, 2005 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
“We believe that this exclusive award to Orchid Cellmark reflects our continued position as one of the most trusted and respected DNA testing providers in the world,” said David Hartshorne, commercial director of Orchid Cellmark’s European business. “Over the last 18 years we have performed hundreds of thousands of DNA paternity tests and have established a solid reputation for the quality and professionalism of our service. This award by the U.K. Child Support Agency reinforces our position as one of the largest providers of paternity and family relationship testing in Britain, paralleling our status as one of the largest providers of these services in the U.S.” Orchid Cellmark’s DNA testing procedures are guided by rigorous quality assurance systems. Accredited by the Department for Constitutional Affairs, Orchid Cellmark’s results are accepted as evidence of paternity in U.K. courts of law. Its U.K. laboratory is accredited to international ISO quality standards ISO9001:2000 and ISO17025, and abides by the voluntary Code of Practice for Genetic Paternity Testers in the U.K. To obtain a private paternity test, prospective customers can contact Orchid Cellmark’s customer service center at +44 (0)1235 528000 or via the internet at www.cellmark.co.uk. DNA samples are obtained through a simple mouth swab collected by a doctor. The confidential, conclusive testing results are returned to customers in approximately five business days. More information about the U.K. Child Support Agency can be found at www.csa.gov.uk. Orchid Cellmark established its European headquarters in 2001 through
the acquisition of U.K.-based Cellmark Diagnostics, among the world's
first commercial DNA testing laboratories. Under the Cellmark brand, it
is one of the largest providers of paternity and relationship testing
services in Europe, providing testing to the general public as well as
under contract to a number of government immigration departments including
the U.K. Government’s Foreign and Commonwealth Office. Orchid Cellmark
is also a leading supplier of forensic DNA profiling for criminal investigation,
a rapidly growing area in which the U.K. is a world leader. In addition,
Orchid Cellmark is a major developer and supplier of agricultural genotyping
services for genetic markers associated with disease resistance, breeding
traits and animal traceability. More information about the range of DNA
testing services and products available from Orchid Cellmark’s European
business can be found at www.orchideurope.com. All statements in this press release
that are not historical are forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act as amended. Such statements
are subject to risks and uncertainties that could cause actual results
to differ materially from those projected, including, but not limited
to, uncertainties relating to technologies, product development, manufacturing,
market acceptance, cost and pricing of Orchid products and services, dependence
on collaborations and partners, regulatory approvals, competition, intellectual
property of others, patent protection, litigation, Orchid’s ability
to obtain additional financing and Orchid’s listing on the Nasdaq
National Market. These risks and other additional factors affecting Orchid’s
business are discussed under the headings "Risks Related to Our Business,"
"Risks Related to the Biotechnology Industry" and "Risks
Associated with Our Common Stock" in Orchid’s Annual Report
on Form 10-K for the year ended December 31, 2002, and Orchid’s Registration
Statement on Form S-3 and the prospectus contained therein dated June
6, 2003, each as filed with the Securities and Exchange Commission, and
in other filings made by Orchid with the Securities and Exchange Commission
from time to time. Orchid expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Orchid’s expectations with
regard thereto or any change in events, conditions, or circumstances on
which any such statements are based, except as may be required by law. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
